Floatz logo

TIL

Toxicity, Drug

Leiden UniversityCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Toxicity, Drug cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
Leiden University
Phase 1/2CCC

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →